| References |
1. Park SI, Kim J, Yu KS, Jang IJ, Lee S. Changes in Cardiac Function After a Single Intravenous Administration of CKD-712 in Healthy Male Volunteers. Clin Drug Investig. 2017 Feb 3. doi: 10.1007/s40261-017-0494-3. [Epub ahead of print] PubMed PMID: 28160190. 2. Lee WS, Yun JW, Nagappan A, Lu JN, Kim MJ, Lee JH, Kim DH, Choi YH, Kim HJ, Chang KC, Jung JM. Synthesized tetrahydroisoquinoline alkaloid exerts anticancer effects at least in part by suppressing NF-κB-regulated proteins in A549 human lung cancer cells. Oncol Rep. 2015 Mar;33(3):1141-6. doi: 10.3892/or.2014.3658. PubMed PMID: 25482101. 3. Kim YM, Tsoyi K, Jang HJ, Park EJ, Park SW, Kim HJ, Hwa JS, Chang KC. CKD712, a synthetic isoquinoline alkaloid, enhances the anti-cancer effects of paclitaxel in MDA-MB-231 cells through regulation of PTEN. Life Sci. 2014 Sep 1;112(1-2):49-58. doi: 10.1016/j.lfs.2014.07.015. PubMed PMID: 25058922. 4. Hsu YH, Chang CC, Yang NJ, Lee YH, Juan SH. RhoA-mediated inhibition of vascular endothelial cell mobility: positive feedback through reduced cytosolic p21 and p27. J Cell Physiol. 2014 Oct;229(10):1455-65. doi: 10.1002/jcp.24583. PubMed PMID: 24535918. |
